Compare Jumia Technologies AG - ADR (JMIA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Recursion Pharmaceuticals Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.15 (market cap $719.58M), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.5× Jumia Technologies AG - ADR's market cap. Which is the better fit depends on your goals.
| JMIA | RXRX | |
|---|---|---|
Market Cap | $719.58M | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $6.79 |
52-Week Low | $5.69 | $2.84 |
Enterprise Value | $666.68M | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.00, down 3.07% today, with a bearish technical signal. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with a -30.79% net margin. Analyst sentiment is positive with 71% buy ratings, supported by progress toward Q4 2026 breakeven targets and recent $50M capital raise.
The path to profitability remains the key investment thesis, with management targeting 2027 EBITDA breakeven. Risks include persistent cash burn, competitive e-commerce landscape, and execution challenges in African markets. The stock offers speculative upside if turnaround continues but carries significant operational risk.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
